Login
$BRVE
$19.49 +$0.00 (0.0%) After hours

$BRVE SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G
16 Nov 2026 SCHEDULE 13G
10 Nov 2026 10-Q
10 Nov 2026 8-K: Results of Operations and Financial Condition

Braveheart Bio Reports Third Quarter 2026 Financial Results and Provides Business Update

09 Nov 2026 SCHEDULE 13G
06 Nov 2026 8-K: Regulation FD Disclosure

Hengrui Pharma and Braveheart Bio Present Data from52-Week Open-Label Extension of Phase 2 Studyof HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific Sessions 2026

05 Nov 2026 SCHEDULE 13G
10 Sep 2026 SCHEDULE 13D/A
08 Sep 2026 10-Q
08 Sep 2026 8-K: Results of Operations and Financial Condition

Phase 3 LIONHEART-HCM Trial of BHB-1893 in Obstructive Hypertrophic Cardiomyopathy (oHCM) Initiated

18 Aug 2026 SCHEDULE 13D
14 Aug 2026 Form 3: Agarwala Vineeta, Director

Holds 10,232,420 shares of Common Stock

14 Aug 2026 SCHEDULE 13D
14 Aug 2026 SCHEDULE 13G
11 Aug 2026 Form 4: Orbimed Advisors Llc, Director and 2 others

Received 9,132,420 shares by conversion · Bought 1,940,000 shares ($34.9M)

11 Aug 2026 Form 4: Ah Bio Fund IV, L.p., 10% owner and 3 others

Received 9,132,420 shares by conversion · Bought 1,100,000 shares ($19.8M)

11 Aug 2026 Form 4: Chimovits Erez, Director

Received 9,132,420 shares by conversion · Bought 1,940,000 shares ($34.9M)

10 Aug 2026 Form 4: Jiangsu Hengrui Pharmaceuticals Co., Ltd., 10% owner

Received 7,420,091 shares by conversion

07 Aug 2026 Form 4: Forbion Growth Opportunities Fund Iii Cooperatief U.a., 10% owner and 3 others

Received 17,123,287 shares by conversion · Bought 3,600,000 shares ($64.8M)

07 Aug 2026 Form 4: Rickey James Paul, Chief Financial Officer

Granted 300,000 Stock Option (Right to Buy) · Bought 27,777 shares ($500K)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support